Chinese orthopedic implant maker selling spine, trauma and joint-replacement devices to hospitals.
Chinese orthopedic implant maker selling spine, trauma and joint-replacement devices to hospitals.
Sells through distributors to hospitals, and government-run volume-based procurement for orthopaedic implants has cut prices in exchange for guaranteed volumes, which favours low-cost domestic makers over imports. Surgeons' familiarity with an implant system and training from the maker help repeat orders.
In one line: A Chinese Stryker Orthopaedics/Zimmer Biomet.
Moat: narrow (regulatory licence, switching costs). Device registration and surgeon training create moderate switching costs.
Headquarters: Xiamen, Fujian, China · Employees: 4,704
Size Double Medical Technology (002901.SZ) is a China Health Care company (Medical Specialties) with a market value of $2.43B, the 984th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥39.54 on 18 Nov 2026.
Performance Over six months the shares fell 2.2%, against +0.5% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 12.8% over the last twelve months (peer median +4.7%); the operating margin is 25.5% (peer median 7.4%).
Valuation It trades at 24.2× forward earnings against a peer median of 24.3× (9th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.7 points above its cost of capital (7.7% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.80B | CN¥2.57B | CN¥2.12B | CN¥1.52B | CN¥1.42B |
| Revenue growth | — | +21% | +39% | +8% | — |
| Gross profit | CN¥2.19B | CN¥1.77B | CN¥1.41B | CN¥997M | CN¥1.05B |
| EBITDA | n/a | CN¥806M | CN¥546M | CN¥202M | CN¥168M |
| Net income | CN¥646M | CN¥600M | CN¥357M | CN¥59.0M | CN¥92.6M |
| Free cash flow | CN¥674M | CN¥702M | CN¥189M | -CN¥220M | -CN¥140M |
| Capital expenditure | CN¥150M | CN¥134M | CN¥270M | CN¥306M | CN¥285M |
| Total debt | CN¥306M | CN¥316M | CN¥385M | CN¥599M | CN¥69.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Double Medical Technology 002901.SZ | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% |
| Zimmer Biomet ZBH | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% |
| Stryker SYK | $121B | -1% | +8% | 25% | 19.9× | 10.7% |
| Shandong Weigao Orthopaedic Device 688161.SS | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% |
| Beijing Chunlizhengda Medical Instruments 1858.HK | $631M | -28% | -9% | 31% | 8.5× | -9.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002901.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.6% | -3.0% | 8th highest of 21 |
| 6-month return | -2.2% | +0.5% | 8th lowest of 21 |
| Distance from 52-week high | -25.7% | -27.0% | 10th highest of 21 |
| Revenue growth (TTM) | +12.8% | +4.7% | 6th highest of 20 |
| Operating margin | 25.5% | 7.4% | 3rd highest of 20 |
| Forward P/E | 24.2× | 24.3× | 9th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 7.6% | 11.9% | 6th least demanding of 14 |
| Growth delivered (Del g) | +10.4% | +10.2% | 7th highest of 14 |
| Hurdle (Req g minus delivered) | -2.8 pp | -2.2 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | +18.7 pp | -0.7 pp | 3rd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 24.0× | n/a | n/a |
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 15.7× | 4.7% | +6.8% |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.25B | -17% | +8% | 29% | 22.1× | -1.1% | +14.1% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% | +8.0% |
| Metall Zug METN.SW | Switzerland | $2.19B | +20% | 0% | -10% | 139.8× | n/a | n/a |
| Celcuity CELC | United States | $2.73B | -60% | n/a | n/a | n/a | n/a | n/a |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% | +0.4% |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | n/a | n/a | n/a |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |